CTIS2023-506163-34-00进行中（未招募）1 期
BIO-PERTUZ-301
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 382
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
招募中
1 期
A study to characterize the pharmacokinetic profile of norucholic acid (NCA) in patients with primary sclerosing cholangitis (PSC)CTIS2023-507027-37-00Dr. Falk Pharma GmbH43
招募中
1 期
A clinical trial to learn how an investigational drug (norucholic acid) is absorbed, distributed, broken down, and removed from the body when given to people with kidney problemsCTIS2023-505862-27-00Dr. Falk Pharma GmbH48
招募中
1 期
A phase 1 study of oral Debio 0123 in combination with carboplatin in patients with advanced solid tumorsPatients with tumorsMedDRA version: 21.1Level: LLTClassification code: 10065147Term: Malignant solid tumor Class: 10029104MedDRA version: 21.1Level: LLTClassification code: 10065252Term: Solid tumor Class: 10029104CTIS2024-510984-52-00Debiopharm International SA115
招募中
1 期
An open-label, phase I/II study of T3P-Y058-739, a genetically-modified strain of the bacterium Yersinia enterocolitica, in patients with advanced solid tumoursCTIS2023-504199-19-00T3 Pharmaceuticals AG100
招募中
1 期
A study of the safety and tolerability of timolol administration by an eye implant in patients with glaucomaGlaucomaMedDRA version: 20.0Level: LLTClassification code: 10030856Term: Open-angle glaucoma Class: 10015919MedDRA version: 26.0Level: PTClassification code: 10048867Term: Pseudophakia Class: 10042613CTIS2024-511254-51-00Eyed Pharma18